• Bending Rigidity of Red Blood Cell Membranes: New Quantitati

  2026-05-30

  This study provides a direct measurement of the bending modulus of the red blood cell cytoplasmic membrane, excluding contributions from the spectrin network and ATP. Using advanced scattering and simulation techniques, the authors report a notably low bending rigidity (4–6 kBT), offering fresh perspectives on red blood cell mechanical properties and their biological implications.

• NMDA (N-Methyl-D-aspartic acid) in Excitotoxicity Research

  2026-05-29

  NMDA (N-Methyl-D-aspartic acid) is the gold-standard NMDA receptor agonist for modeling excitotoxicity, calcium influx, and oxidative stress in neurodegenerative disease research. Learn how to leverage APExBIO’s high-purity NMDA for reproducible workflows, nuanced troubleshooting, and experimental designs inspired by the latest advances in glaucoma and retinal ganglion cell studies.

• Caspase-4 Colorimetric Assay: Driving Translational Pyroptos

  2026-05-29

  Explore the mechanistic, technical, and translational frontiers of caspase-4 biology and pyroptosis with a deep dive into LEVD-dependent enzyme assays. This article delivers strategic guidance for researchers seeking to bridge bench and bedside in inflammation and cell fate modulation, highlighting the pivotal role of APExBIO’s Caspase-4 Colorimetric Assay Kit in advancing biomarker detection and experimental rigor.

• Isoliensinine Mitigates LPS-Induced Neuroinflammation via MA

  2026-05-28

  This study reveals that isoliensinine, a bisbenzylisoquinoline alkaloid, confers neuroprotection by attenuating LPS-induced neuroinflammation in microglia through inhibition of the MAPK/NF-κB pathway. The findings highlight isoliensinine's impact on oxidative stress and mitochondrial dysfunction, supporting its potential as a candidate for further research in Alzheimer's disease models.

• Antidepressant Effects of Rotigotine in Experimental Depress

  2026-05-28

  This study demonstrates that rotigotine, a dopamine D2/D3 receptor agonist, possesses antidepressant-like properties in validated rodent models of depression, with efficacy at sub-hyperlocomotor doses. These results highlight the compound's potential to address depressive symptoms that frequently overlap with Parkinson's disease, expanding its relevance beyond traditional antiparkinsonian use.

• Acifran: Precision Tool for Lipid Metabolism Research Workfl

  2026-05-27

  Acifran, a selective HM74A/GPR109A and GPR109B agonist, unlocks new precision in lipid metabolism research with structural validation and robust assay performance. Its unique profile empowers advanced GPCR signaling studies and next-generation metabolic disorder research. Discover protocol enhancements, troubleshooting strategies, and practical insights for maximizing its impact.

• Crystal Violet Staining Solution: Precision in Nuclear Stain

  2026-05-27

  Crystal Violet Staining Solution empowers researchers to achieve robust, reproducible nuclear staining in cell-based and tissue assays. By optimizing protocol parameters and understanding comparative dye performance, scientists can maximize data clarity and troubleshoot workflow bottlenecks in both classic and advanced experimental setups.

• Praeruptorin A Inhibits HCC Metastasis via ERK/MMP1 Modulati

  2026-05-26

  This study demonstrates that praeruptorin A suppresses migration and invasion in human hepatocellular carcinoma (HCC) cells by downregulating MMP1 through ERK pathway activation. The results highlight a mechanistically distinct, non-cytotoxic approach to targeting HCC metastasis, providing a promising direction for future hepatoprotective agent development.

• E-64d: Applied Cysteine Protease Inhibition in Cell Death As

  2026-05-26

  E-64d enables precise, membrane-permeable inhibition of calpain and cathepsins, unlocking new experimental designs in apoptosis, neuroprotection, and lysoptosis research. This guide details real-world workflows, troubleshooting, and data-backed parameters to help researchers maximize assay reproducibility and mechanistic insight.

• Targeted mRNA Delivery to Islet β Cells via Conjugated LNPs

  2026-05-25

  Enriquez et al. introduce a lipid nanoparticle platform engineered for β cell-enriched mRNA delivery, demonstrating targeted transfection in both mouse and human islets. Their approach, including eGLP-1 surface conjugation, enabled functional mRNA delivery in vivo and delayed autoimmune diabetes progression in mice, highlighting a new avenue for β cell-directed gene therapy.

• Bufuralol Hydrochloride: Next-Gen β-Adrenergic Modulation In

  2026-05-25

  Explore the distinct mechanisms and advanced research applications of Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, with a unique focus on protocol parameters and organoid-based pharmacokinetics. Discover how APExBIO’s product enables nuanced cardiovascular pharmacology research.

• Ionisable Lipid Variations Shape LNP Efficacy for mRNA Deliv

  2026-05-24

  This study systematically investigates how structural differences in ionisable lipids and sterols within lipid nanoparticles (LNPs) affect the encapsulation, cellular expression, and biodistribution of mRNA. The findings provide new insight into optimizing LNP design for effective mRNA delivery and highlight the complexities of translating in vitro success to in vivo performance.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Practical Use Guide

  2026-05-23

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) addresses the need for reliable, high-specificity detection of mouse IgG in immunoassays such as Western blot, ELISA, and IHC. It should be used in workflows requiring signal amplification with horseradish peroxidase-conjugated secondary antibodies, but not where direct primary antibody detection or non-mouse targets are involved.

• Redefining Senescence Assays: Lysosomal β-Galactosidase for

  2026-05-22

  This thought-leadership article advances the discussion on cellular senescence assays by dissecting the mechanistic basis and translational implications of lysosomal β-galactosidase staining. Drawing on recent oncology research, including the role of SLC25A1-driven senescence in chemoresistance, it offers strategic guidance for assay selection and experimental design. The piece spotlights the APExBIO Lysosomal β-Galactosidase Staining Kit, setting a new benchmark for artifact-free, reproducible workflows and control validation, and bridges the gap between experimental rigor and clinical relevance.

• Assessing Ribociclib–Acid Reducer Interactions with QbD Anal

  2026-05-22

  This study applies an Analytical Quality by Design (QbD) approach to rigorously evaluate whether acid-reducing agents significantly alter the solubility and absorption of ribociclib succinate, a weakly basic CDK4/6 inhibitor, under physiologically relevant pH conditions. Findings indicate that pH shifts from acid-reducing agents do not substantially impact ribociclib’s absorption, offering a framework for predicting drug–drug interactions in oncology.

11723 records 1/782 page Next 12345 下5页 Last page